Metabolic Disorder Drugs Market Global Briefing 2017Including: Anti-diabetics drugs, Anti-thyroid drugs, and Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism).Covering: Sanofi S.A., Novo Nordisk A/S, AstraZeneca Plc., Johnson & Johnson, Merck & Co., Abbott Laboratories Inc., Boehringer Ingelheim GmbH, AbbVie Inc., Takeda Pharmaceuticals, Pfizer Inc., Bayer AG
The global metabolic disorder drugs market is expected to reach around $110 billion in 2020. The market is expected to be driven by rapid growth in diabetic patients which, according to the World Health Organization, is expected to be the world’s seventh leading cause of death in 2030.
Metabolic Disorder Drugs Market Global Briefing provides strategists, marketers and senior management with the critical information they need to assess the global metabolic disorder drugs sector.
Reasons to Purchase
Get up to date information available on the metabolic disorder drugs market globally.
Identify growth segments and opportunities.
Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
Develop strategies based on likely future developments.
Gain a global perspective on the development of the market.
Metabolic Disorder Drugs Market Global Briefing from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.
The market characteristics section of the report defines and explains the market.
The market size section gives the metabolic disorder drugs market revenues, covering both the historic growth of the market and forecasting the future.
Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.
The trends and strategies section highlights the likely future developments in the metabolic disorder drugs market and suggests approaches.
Markets Covered: Anti-diabetics drugs, Anti-thyroid drugs, and Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism). Companies Mentioned: Sanofi S.A., Novo Nordisk A/S, AstraZeneca Plc., Johnson & Johnson, Merck & Co., Abbott Laboratories Inc., Boehringer Ingelheim GmbH, AbbVie Inc., Takeda Pharmaceuticals, Pfizer Inc., Bayer AG Geographic scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa Time series: Five years historic and forecast. Data: Market value in $ billions. Data segmentations: Regional breakdowns, market share of competitors, key sub segments. Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.